The global arterial cannula market size was valued at USD 19.2 million in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 7.2% from 2023 to 2030. The increasing prevalence of chronic disorders that require cardiopulmonary pass surgery (CABG), dialysis, and Extracorporeal Membrane Oxygenation (ECMO) is primarily driving the demand for arterial cannula. There is arise in preference for minimally invasive techniques due to advantages, such as less recovery and less pain. The COVID-19 pandemic had a negative impact on the industry. The pandemic resulted in a precipitous decline in hospitalizations for myocardial infarction and revascularization procedures.
In addition, as part of resource prioritization and infection control, there had been a precautionary postponement of elective procedures, including CABG. According to a research article published by the American Association of Thoracic Surgery, in June 2021, there was a 36% decline in CABG volume in 2020 in the U.S. due to the COVID-19 pandemic.However, in 2021, the industry managed to recover significantly due to the opening of the economies and attempts to overcome the huge backlog that resulted due to the outbreak of the COVID-19 pandemic. Moreover, studies have suggested that the COVID-19 virus does not only affect the lungs but can also cause severe harm to other organs, including the heart and kidneys.
Studies indicate that more than 50% of patients in the intensive care unit with kidney injury may require dialysis and more than 30% of patients hospitalized with COVID-19 develop kidney injury. Thus, this indicates that the patients that have been severely infected with the virus are likely to face health issues related to the heart and kidneys, which may require dialysis and CABG. This further has accelerated the product demand. There is an increased prevalence of heart disorders worldwide due to the lack of physical activities, smoking, poor nutrition, obesity, or family history. Other risk factors for cardiovascular disorders comprise hypertension, diabetes, or hyperlipidemia.
According to a research study published in the European Journal of Preventive Cardiology, the official journal of the European Association of Preventive Cardiology, more than 90 percent of people with type 2 diabetes (T2D) are at high risk of fatal heart disease or stroke within 10 years. Thus, an increase in risk factors, such as diabetes and hypertension, is likely to lead to a rise in the prevalence of Cardiovascular Diseases (CVDs), which will boost the product demand over the forecast period.An increasing geriatric population that is highly vulnerable to developing chronic diseases is also contributing to the growth of the industry. According to the U.S. Census Bureau, there were about 40.3 million U.S. residents aged 65 years and older in 2010 and the number rose to 54.1 million in July 2019. Asian countries like Japan, China, and India have a huge geriatric population, which represents lucrative growth opportunities for the industry in this region.
On the basis of applications, the industry has been further segmented into cardiopulmonary bypass surgery, ECMO, and others. The ECMO segment dominated the global industry in 2022 and accounted for the maximum share of more than 42.0% of the overall revenue. This can be attributed to the high prevalence of cardiac diseases and lung failures. According to the American Lung Association’s estimated data in 2022, around 37 million Americans live with chronic lung disease like COPD and asthma, which includes chronic bronchitis and emphysema. About 15 million American adults have been diagnosed with COPD, an obstructive lung disease that over time makes it harder to breathe.
This suggests that the increasing burden of respiratory diseases that may eventually result in lung failure is the major factor contributing to the dominance of the ECMO segment. On the other hand, cardiopulmonary bypass surgery is expected to be the fastest-growing segment over the forecast period. This is due to the rising prevalence of cardiac diseases that require cardiopulmonary bypass surgery. According to a research article, published by the National Centers for Biotechnology Information published in May 2022, almost 400,000 CABG surgeries are performed annually making it the most commonly performed major surgical procedure.
On the basis of sizes, the global industry has been further categorized into 14-16 Fr, 17-19 Fr, 20-22 Fr, 23-25 Fr, 26-28 Fr, 29- 31 Fr, 32-34 Fr and 35-36 Fr. The 20-22 Fr size segment dominated the global industry in 2022 and accounted for the highest share of more than 23.00% of the overall revenue. The high share of the segment can be attributed to an increase in the adoption of cannulas of this size while carrying out ECMO procedures. The demand for these cannulas experienced a sudden rise during the pandemic as a higher number of patients required ECMO, especially those who were infected with the virus.
While selecting the size, the general rule that healthcare professionals need to abide by is to select the smallest possible size but the one which allows effective drainage. The 23-25 Fr size segment accounted for the second-highest revenue share of the global industry in 2022. This was due to the wide usage of these cannulas in cardiopulmonary bypass surgeries. On the other hand, the 35-36 Fr size segment is estimated to register the fastest growth rate during the forecast period.
On the basis of end-uses, the global industry has been further categorized into hospitals, Ambulatory Surgical Centers (ASCs), and others. The hospitals segment dominated the industry in 2022 and accounted for the highest share of more than 55.50% of the overall revenue. This was mainly attributed to alarge number of surgeries being performed in these settings. In addition, the availability of all types of skilled professionals and surgical instruments is expected to fuel the segment's growth. The rising number of admissions due to an increasing number of chronic disorders is also expected to propel the segment growth over the forecast period.
The ASCs segment is also expected to gain significant growth over the forecast period owing to the increasing preference of individuals to undergo surgical interventions in ASCs. Some of the reasons for this increasing shift towards ASCs include reduced overall cost and hospitalization span of the patient post-surgery. Moreover, favorable government initiatives are further contributing to the growth of the segment over the forecast period. For instance, in early 2021, the Centers for Medicare and Medicaid Services expanded ASC coverage for cardiac interventional procedures including endovenous ablation, catheterization procedures, and pacemaker placements.
North America held the highest revenue share of more than 40.70% in 2022 owing to the rising cardiac surgery volumes and high prevalence of chronic kidney diseases in the region. According to the CDC, in 2018, there were 7,433 dialysis facilities in the United States, of which 518,749 patients underwent dialysis. The average number of patients per facility in the United States was approximately 70.Moreover, pulmonary diseases like COPD and Asthma that may result in lung failure are also significantly high in this region. Europe accounted for the second-largest share, in terms of revenue. Factors, such as the rising geriatric population, especially in countries like Italy, growing government initiatives, and favorable reimbursement scenarios drive the region’s growth.
For instance, according to MedTech Europe, the European trade association for medical technology, France implemented the 2018-2022 National Health Strategy for the prevention of cardiovascular risks by supporting changing lifestyle habits. Asia Pacific is expected to register the maximum CAGR over the forecast period. Factors, such as a large patient pool for cardiovascular & chronic kidney diseases and increasing disposable income are major factors driving the industry growth. For instance, according to a research study published in 2022, an estimated 434.3 million people had CKD across the eastern, southern, and south-eastern regions of Asia, with most of the disease burden observed in India and China (up to 299.9 million).
Key players are keenly focused on carrying out strategic initiatives, such as acquisitions and partnerships & collaborations, that will help them expand their industry presence and secure a strong position in the market. Moreover, with the launch of new products and regulatory approvals, key players are aiming at broadening their portfolio, which will strengthen their presence. For instance, in April 2020, LivaNova Plc. received a CE mark for its Bi-Flow Extracorporeal Membrane Oxygenation (ECMO) cannula for ECMO procedures, in which, femoral artery cannulation can be applied. Some prominent players in the global arterial cannula market include:
Fresenius Medical Care
Freelife Medical GmbH
Market size value in 2023
USD 20.48 million
Revenue forecast in 2030
USD 33.4 million
CAGR of 7.2% from 2023 to 2030
Base year for estimation
2017 - 2021
2023 - 2030
Revenue in USD millionand CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Application, size, end-use, region
North America; Europe; Asia Pacific; Latin America; Middle East & Africa
U.S.; Canada; U.K.; Germany; France; Italy; Spain; China; India; Japan; Mexico; Brazil; Argentina; South Africa; Saudi Arabia; UAE
Key companies profiled
Medtronic, plc; LivaNova plc; Edward Lifesciences; Getinge AB; Fresenius Medical Care; BD; Nipro Corp.; Andocor; Freelife Medical GmbH; Surgical Holdings; Kangxin Medical
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For the purpose of this study, Grand View Research has segmented the global arterial cannula market report on the basis of application, size, end-use, and region:
Application Outlook (Revenue, USD Million, 2017 - 2030)
Cardiopulmonary Bypass Surgery
Extracorporeal Membrane Oxygenation (ECMO)
Size Outlook (Revenue, USD Million, 2017 - 2030)
29- 31 Fr
End-use Outlook (Revenue, USD Million, 2017 - 2030)
Ambulatory Surgical Centers
Regional Outlook ((Revenue, USD Million, 2017 - 2030)
Middle East & Africa
b. The global arterial cannula market size was estimated at USD 19.28 million in 2022 and is expected to reach USD 20.48 million in 2023.
b. The global arterial cannula market is expected to grow at a compound annual growth rate of 7.3% from 2023 to 2030 to reach USD 33.43 million by 2030.
b. North America dominated the arterial cannula market with a share of 40.71% in 2022. This is attributable to the increasing prevalence of cardiac surgeries and chronic kidney diseases and increasing healthcare expenditure.
b. Some key players operating in the arterial cannula market include Medtronic, plc., LivaNova plc, Edward Lifesciences, Getinge AB, Fresenius Medical Care, BD, Nipro Corporation, Andocor, Freelife Medical GmbH, Surgical Holdings, and Kangxin Medical.
b. Key factors that are driving the arterial cannula market growth include an increasing number of surgical procedures, advancements in minimally invasive surgeries and increasing prevalence of chronic diseases.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."